708 ETN0001 domain-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 36 | 18.4 | 1.96× | q < 0.0001 | |
| Organic acids and derivatives | 6 | 5.8 | 1.03× | q = 0.88 | |
| Organoheterocyclic compounds | 4 | 5.8 | 0.69× | q = 0.72 | |
| Organic oxygen compounds | 2 | 7.5 | 0.27× | q = 0.04 | |
| Homogeneous non-metal compounds | 2 | 8.1 | 0.25× | q = 0.03 | |
| Nucleosides, nucleotides, and analogues | 2 | 10.4 | 0.19× | q = 2.2e-3 | |
| Organohalogen compounds | 1 | 0.1 | 9.37× | not tested | |
| Organosulfur compounds | 1 | 0.8 | 1.30× | not tested | |
| Benzenoids | 1 | 2.7 | 0.36× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB04137 | GTP | Guanosine-5'-Triphosphate | 7 |
| DB01960 | M7G | 7-methyl-7,8-dihydroguanosine-5'-diphosphate | 6 |
| DB12101 | 8W7 | Iberdomide | 5 |
| DB00143 | GSH | Glutathione | 4 |
| DB17584 | QFC | Mezigdomide | 4 |
| DB02256 | DUR | 2'-Deoxyuridine | 3 |
| DB19152 | BAQ | Pyrrolidone | 3 |
| DB03345 | BME | Mercaptoethanol | 2 |
| DB04149 | ROL | (R)-Rolipram | 2 |
| DB04447 | DTT | 1,4-Dithiothreitol | 2 |
| DB00128 | ASP | Aspartic acid | 1 |
| DB00139 | SIN | Succinic acid | 1 |
| DB00480 | — | — | 1 |
| DB01041 | — | — | 1 |
| DB03226 | ETF | Trifluoroethanol | 1 |
| DB08910 | — | — | 1 |
| DB11093 | — | — | 1 |
| DB11348 | — | — | 1 |
| DB14481 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ZNmetal | ZINC ION | 573 |
| EF2 | S-Thalidomide | 74 |
| Y70 | S-Pomalidomide | 22 |
| CL | CHLORIDE ION | 20 |
| 6EL | 2-[(3~{R})-2,6-bis(oxidanylidene)piperidin-3-yl]isoindole-1,3-dione | 16 |
| HGmetal | MERCURY (II) ION | 14 |
| RN9 | 3-[3-[[1-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2,5-bis(oxidanylidene)pyrrol-3-yl]amino]phenyl]-~{N}-(3-chloranyl-4-methyl-phenyl)propanamide | 12 |
| LVY | S-Lenalidomide | 10 |
| GTP | GUANOSINE-5'-TRIPHOSPHATE | 9 |
| MGmetal | MAGNESIUM ION | 9 |
| QFC | Mezigdomide | 9 |
| 8W7 | (3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione | 7 |
| A1A0J | (3S)-3-(3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-1-yl)piperidine-2,6-dione | 6 |
| AUmetal | GOLD ION | 6 |
| M7G | 7N-METHYL-8-HYDROGUANOSINE-5'-DIPHOSPHATE | 6 |
| A1IW1 | (3~{S})-3-[3-oxidanylidene-5-[8-(phenylcarbonyl)-2,8-diazaspiro[4.5]decan-2-yl]-1~{H}-isoindol-2-yl]piperidine-2,6-dione | 4 |
| GSH | Glutathione | 4 |
| JNW | 2-[[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamoyl]benzoic acid | 4 |
| 85C | 1-(3-chloro-4-methylphenyl)-3-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}methyl)urea | 3 |
| 9FT | (3R)-3-(4-methoxyphenyl)piperidine-2,6-dione | 3 |